Audience

HCP Dermatologists panel (US)

HCP Dermatologists (US): a public Ask Brox audience of Brox clones, each built from a long-form interview with a real person. Every insight fielded on this panel, newest first.

4 insights·0 studies

What did the HCP Dermatologists panel say?

  1. #

    88.9%

    For a healthy 35-year-old with moderate-to-severe eczema who dislikes injections and asks for a pill, 88.9% of US dermatologists would start an oral JAK inhibitor rather than an injectable biologic when both cost the patient $0 a month; 81.7% still would when the JAK costs $30 a month more, 69.0% at $75 more and 46.8% at $150 more. — Oral JAK inhibitor or biologic: 88.9% of US dermatologists start a pill-seeking eczema patient on the JAK, and only a $150 a month gap tips most to the biologic

    base 126

  2. #

    90.6%

    90.6% of US dermatologists say that, between two psoriasis biologics with similar efficacy and safety, which one the patient's insurance plan prefers or approves with the least prior authorization decides which they start — Dermatologists let the insurance plan pick between similar psoriasis biologics: 90.6% say the plan decides, and a $25 a month cost gap makes 86.3% very likely to switch

    base 117

  3. #

    66.1%

    66.1% of US dermatologists say insurance requirements or prior authorization are what most often make them hold off moving an adult with moderate eczema from topicals to a systemic — Insurance, not clinical doubt, is what holds back 66.1% of US dermatologists from moving moderate eczema patients off topicals and onto a systemic

    base 127

  4. #

    40.9%

    Asked which one factor carries the most weight when they choose a systemic agent for moderate-to-severe inflammatory skin disease, 40.9% of US dermatologists name safety and the side-effect profile, 33.1% efficacy in trial data and their own experience, 18.9% whether the patient's insurance will cover it without a fight, 2.4% what the patient asks for and 2.4% what the patient will pay out of pocket; ease of administration (1.6%) and speed of onset (0.8%) trail. — US dermatologists put safety first (40.9%) and patient cost last (2.4%) when choosing a systemic therapy, yet 46.9% say coverage or cost overrode that choice in about half or more of their starts

    base 127

What has Brox published on hcp dermatologists panel (us)?Newest first

What do people ask about hcp dermatologists panel (us)?

What makes a dermatologist choose a JAK inhibitor over a biologic, and what makes them avoid it?
88.9% of US dermatologists on the Brox panel would start a healthy 35-year-old with moderate-to-severe eczema who asks for a pill on an oral JAK inhibitor rather than an injectable biologic when both cost the patient $0 a month, falling to 81.7% at a $30 monthly gap, 69.0% at $75 and 46.8% at $150 (n=126, November 2026).Read the insight
How do specialists decide which of several similar biologics to start a new patient on?
When two psoriasis biologics have similar efficacy and safety, 90.6% of US dermatologists say the insurance plan's preference decides which one they start (n=117, October 2026), and 86.3% are very likely to switch to the plan-preferred biologic when their own choice would cost the patient just $25 a month more.Read the insight
How do dermatologists decide when a patient with moderate eczema should move from topicals to a systemic?
Insurance requirements and prior authorization are what most often make 66.1% of US dermatologists hold off moving an adult with moderate eczema from topicals to a systemic (n=127, October 2026), against 3.1% who name safety, while the trigger itself splits between a failed topical trial (51.6%) and itch or sleep loss (42.9%, n=126).Read the insight
How do US dermatologists weigh cost, coverage and safety when starting a systemic therapy?
Asked which one factor carries the most weight when starting a patient on a systemic therapy, 40.9% of US dermatologists name safety and 33.1% efficacy, with insurance coverage at 18.9% and the patient's out-of-pocket cost at 2.4% (n=127, September 2026), yet 46.9% say coverage or cost put a patient on something other than their clinical first choice in about half or more of their starts over the last year, and a $75 monthly out-of-pocket difference cuts the share who would simply prescribe their preferred agent from 69.3% to 12.6%.Read the insight

Other audiences

How should you read these findings?

Where the numbers come from. Every figure on this site is a predicted response from Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The base under each figure is the number of clones behind it.

Where the real data comes from. The long-form video interviews with the real people the clones are built from. A quote is always shown with the interview line it was predicted from.

What you can take away. Insights publish their tabulation as CSV and JSON: question, option, count, percentage and base. Never per-person rows.

Ask this of your own customers: humans@brox.ai